{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:30:54Z","timestamp":1790483454497,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,10]]},"DOI":"10.7759\/cureus.98935","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:30:58Z","timestamp":1765431058000},"source":"Crossref","is-referenced-by-count":2,"title":["Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Shamsun","family":"Nahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Maybee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowrin","family":"Tamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Sadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjana","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokeya","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sume","family":"Akther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishma Salsabil","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsun Nahar","family":"Sonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.003","article-title":"Prevalence of antiobesity treatment and weight-inducing antihyperglycemic agents among patients with type 2 diabetes in the United States","volume":"44","author":"Levin A","year":"2022","unstructured":"Levin A, Kaur N, Mainoo NK, Perez A. Prevalence of antiobesity treatment and weight-inducing antihyperglycemic agents among patients with type 2 diabetes in the United States. Clin Ther. 2022, 44:35-44. 10.1016\/j.clinthera.2022.01.003","journal-title":"Clin Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu MS","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023, 24:10449. 10.3390\/ijms241310449","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris N","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024, 75:102782. 10.1016\/j.eclinm.2024.102782","journal-title":"EClinicalMedicine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024, 9:957-64. 10.1016\/S2468-1253(24)00188-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll H","year":"2024","unstructured":"Moll H, Frey E, Gerber P, et al.. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024, 73:102661. 10.1016\/j.eclinm.2024.102661","journal-title":"EClinicalMedicine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46091","article-title":"Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis","volume":"15","author":"Karrar HR","year":"2023","unstructured":"Karrar HR, Nouh MI, Nouh YI, et al.. Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis. Cureus. 2023, 15:e46091. 10.7759\/cureus.46091","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian D","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al.. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Clin Nutr. 2025, 122:344-67. 10.1016\/j.ajcnut.2025.04.023","journal-title":"Am J Clin Nutr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:10145. 10.3390\/jcm12010145","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81891","article-title":"GLP-1 receptor agonists in diabetes and obesity: a case report and review of bowel obstruction risks and management","volume":"17","author":"Jones M","year":"2025","unstructured":"Jones M, Cappola JJ. GLP-1 receptor agonists in diabetes and obesity: a case report and review of bowel obstruction risks and management. Cureus. 2025, 17:e81891. 10.7759\/cureus.81891","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02006","article-title":"Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans","volume":"103","author":"Halim MA","year":"2018","unstructured":"Halim MA, Degerblad M, Sundbom M, et al.. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab. 2018, 103:575-85. 10.1210\/jc.2017-02006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88589","article-title":"Weighing the risks: Small bowel obstruction associated with semaglutide use in the postoperative abdomen","volume":"17","author":"Nagib N","year":"2025","unstructured":"Nagib N, Avila D, Partyka J, Kamyab A. Weighing the risks: Small bowel obstruction associated with semaglutide use in the postoperative abdomen. Cureus. 2025, 17:e88589. 10.7759\/cureus.88589","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001679","article-title":"From glycemic control to gut telescoping: intussusception in a patient on a glucagon-like peptide-1 receptor agonist","volume":"12","author":"Thakkar B","year":"2025","unstructured":"Thakkar B, Nguyen MT, Hagen R, Parikh N. From glycemic control to gut telescoping: intussusception in a patient on a glucagon-like peptide-1 receptor agonist. ACG Case Rep J. 2025, 12:e01679. 10.14309\/crj.0000000000001679","journal-title":"ACG Case Rep J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.07.1569","article-title":"A rare case of a large bowel obstruction due to tirzepatide","volume":"4","author":"Gordon A","year":"2023","unstructured":"Gordon A, Dixit K, Shachi T, Salonia J, Seltzer E. A rare case of a large bowel obstruction due to tirzepatide. Chest. 2023, 4:2334-5. 10.1016\/j.chest.2023.07.1569","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.128","article-title":"SAT680 Mounjaro: a side effect","volume":"7","author":"Rao K","year":"2023","unstructured":"Rao K, Nimako EK. SAT680 Mounjaro: a side effect. J Endocr Soc. 2023, 7:114-28. 10.1210\/jendso\/bvad114.128","journal-title":"J Endocr Soc"},{"key":"ref17","article-title":"Case report: small bowel obstruction after starting tirzepatide (Mounjaro)","volume":"110","author":"Morgenthaler L","year":"2024","unstructured":"Morgenthaler L, DePietro R. Case report: small bowel obstruction after starting tirzepatide (Mounjaro). Am Fam Physician. 2024, 110:562.","journal-title":"Am Fam Physician"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88350","article-title":"Semaglutide-induced small bowel pseudo-obstruction and ileitis in a patient with type 2 diabetes: a case report","volume":"17","author":"Javed F","year":"2025","unstructured":"Javed F, Shaat IA, Oyibo SO. Semaglutide-induced small bowel pseudo-obstruction and ileitis in a patient with type 2 diabetes: a case report. Cureus. 2025, 17:e88350. 10.7759\/cureus.88350","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437468-severe-small-bowel-obstruction-in-a-high-risk-patient-on-long-term-tirzepatide-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:31:00Z","timestamp":1765431060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437468-severe-small-bowel-obstruction-in-a-high-risk-patient-on-long-term-tirzepatide-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.98935","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}